TG Therapeutics announced a 2026 U.S. net revenue target of $890 million to $905 million for its multiple sclerosis therapy BRIUMVI on August 3, 2026. The biopharmaceutical company anticipates Phase III trial results for a subcutaneous formulation of the drug around the end of the year. This formulation could significantly improve patient convenience and expand the drug's commercial potential. TG Therapeutics stock traded at $149.12, up 3.19% on the day, as of 15:59 UTC today.
Context — [why this matters now]
The multiple sclerosis treatment market is highly competitive, dominated by entrenched players like Roche with Ocrevus and Novartis with Kesimpta. TG Therapeutics launched BRIUMVI, a CD20-directed monoclonal antibody, as a challenger in this space. The drug's primary differentiator has been its dosing schedule, requiring shorter infusion times than some competitors. The development of a subcutaneous version represents a critical strategic move to increase accessibility and convenience, potentially capturing a larger patient share.
The current macro backdrop for biotech equities remains sensitive to interest rate expectations, with the sector often trading on clinical catalysts rather than macro data. TG Therapeutics' revenue guidance provides a concrete financial benchmark for investors assessing the company's commercial execution. The timing of this announcement, just months ahead of a major clinical readout, positions the company to capitalize on positive data should the subcutaneous trial meet its endpoints.
Data — [what the numbers show]
TG Therapeutics' revenue guidance places 2026 U.S. BRIUMVI sales between $890 million and $905 million. The company's stock price reacted positively to the news, trading at $149.12 with a daily gain of 3.19%. The intraday range was $147.61 to $150.07, indicating strong buying interest near the session's high. This price movement contrasts with the broader biotech sector, which has seen mixed performance amid shifting regulatory and reimbursement landscapes.
This revenue projection implies significant year-over-year growth, building upon the drug's initial launch trajectory. The potential subcutaneous formulation aims to address a key limitation of intravenous therapies, which require patients to visit infusion centers. Successful development could open access to a broader set of treatment settings and patients who prefer at-home administration options.
| Metric | Value |
|---|
| 2026 U.S. BRIUMVI Revenue Target | $890M - $905M |
| TGTX Stock Price | $149.12 |
| TGTX Daily Gain | +3.19% |
Analysis — [what it means for markets / sectors / tickers]
The reaffirmed revenue target and upcoming catalyst are bullish for TG Therapeutics, suggesting strong underlying demand for BRIUMVI. Positive subcutaneous data could force analysts to upgrade long-term sales forecasts, potentially justifying a higher valuation multiple for TGTX. Conversely, competing MS therapy providers like Roche (RHHBY) and Novartis (NVS) could face incremental commercial pressure if TG Therapeutics captures additional market share.
A key risk to this outlook is the clinical trial outcome itself; failure of the subcutaneous formulation to demonstrate non-inferiority to the intravenous version would likely temper growth expectations and represent a significant setback. The market's positive reaction indicates that investors are positioning for a successful data readout, with flow likely moving into TGTX and out of more established peers in the neurology space. The stock's ability to hold near its daily high of $150.07 suggests technical momentum is building.
Outlook — [what to watch next]
The primary catalyst for TG Therapeutics is the topline results from the Phase III trial of subcutaneous BRIUMVI, expected around December 2026. Investors should monitor for any updates on the timing of this data release during the company's next earnings call. Following the data, the company will likely file for regulatory approval with the U.S. Food and Drug Administration in early 2027.
Key levels to watch for TGTX stock include the psychological resistance at $150, a break above which could target its 52-week high. On the downside, support resides near the $145 level, which has previously acted as a consolidation zone. The stock's performance will remain tightly coupled to prescription trend data for BRIUMVI and any commentary from management on market share gains.
Frequently Asked Questions
What is BRIUMVI used for?
BRIUMVI (ublituximab) is a prescription medicine used to treat relapsing forms of multiple sclerosis in adults. It is a CD20-directed cytolytic monoclonal antibody that works by depleting B-cells, which are thought to be involved in the inflammatory process of MS. It is administered via intravenous infusion typically lasting one hour.
How does a subcutaneous version differ from the current treatment?
The current formulation of BRIUMVI requires patients to receive intravenous infusions at a clinic or hospital. A subcutaneous version would be administered as an injection under the skin, potentially allowing for at-home self-administration. This greatly improves convenience for patients, reduces the burden on healthcare facilities, and could improve adherence to treatment regimens.
What does this mean for other multiple sclerosis drug manufacturers?
The commercial success of BRIUMVI, particularly with a more convenient formulation, presents a competitive threat to other leading MS therapies. Drugs like Roche's Ocrevus and Novartis's Kesimpta may experience pricing pressure or market share erosion. The entire competitive landscape could shift toward subcutaneous administration, forcing other manufacturers to accelerate their own development of easier-to-use formulations.
Bottom Line
TG Therapeutics' $900 million revenue target hinges on successfully expanding BRIUMVI's delivery beyond infusion centers.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
